| Name | Title | Contact Details |
|---|
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
Citizens Choice Healthplan is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AlphaVax is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
GHX is a software-as-a-service company that`s reducing the cost of doing business in healthcare by automating supply chain processes and improving visibility into the products used in patient care. We`ve built the GHX Global Network, the world`s largest community of healthcare trading partners, connecting supply chain, finance and clinical professionals with their suppliers. Our cloud-based technology makes it easier for customers to drive costs out of the healthcare supply chain. Since 2010, we`ve saved the healthcare industry $5+ billion. Today we`re expanding our solutions to further enhance data management and allow integration of clinical and business systems. The Industry We Serve Our focus is on the healthcare supply chain, through which hospitals and their suppliers buy and deliver the thousands of medical-surgical supplies that clinicians need to effectively care for patients. For most hospitals, supply chain costs are the second largest and fastest growing operational expense, so reining in these costs is imperative. Our Products and Services At the heart of GHX is the GHX Exchange, a platform that connects healthcare providers and suppliers so they can work together electronically. This helps lower costs and simplifies supply chain management by eliminating error-prone, manual order processes. GHX solutions include: • An open and neutral electronic trading exchange • Procurement and accounts payable automation • Content, contract and inventory management • Business intelligence and reporting • Standards enablement and data synchronization